|
|
 |
Abstracts
Programme at a glance
Thursday Friday
Saturday Sunday Monday
Saturday 10th May 2003
08:00 - 09:00 POSTERS
WORKSHOP
EUROPEAN ACTION TOWARDS BETTER MUSCULOSKELETAL HEALTH:
DEVELOPING A PUBLIC HEALTH STRATEGY TO REDUCE THE BURDEN OF MUSCULOSKELETAL CONDITIONS -
THE EUROPEAN BONE & JOINT HEALTH STRATEGIES PROJECT
Chair: A. D. Woolf (Truro)
08:15 - 09:00 Main Auditorium
W-1
The bone and joint decade – an update
A. D. Woolf (Truro, UK)
The need for strategies to prevent and treat
musculoskeletal conditions
K. Åkesson (Malmö, Sweden)
The Bone and Joint Decade, what is the impact of musculoskeletal
conditions? What are the trends? What are the aims and methods of the European Bone and
Joint Health Strategies Project?
How can we prevent musculoskeletal conditions – trauma, back
pain, osteoporosis, fragility fractures and joint disease?
J. Compston (Cambridge, UK)
What interventions for the whole population are effective? What is
the evidence that early treatment of the various musculoskeletal conditions results in a
better outcome? How can you facilitate early treatment? How do we identify those who
will benefit most?
How to implement health strategies to improve outcome of care?
A. D. Woolf (Truro, UK)
What health strategies and how to implement them? What barriers
and what facilitators? What are the long-term benefits?
SYMPOSIUM 3
OSTEOCLASTS
Chairs: R. Baron (New Haven CT, USA)
A. Zallone (Bari, Italy)
09:00 - 10:00 Main Auditorium
09:00 I-12 Development of novel
anti-resorptive therapies targeting the RANKL-RANK signaling pathway: from
functional genomics to bedside
D. Lacey (Thousand Oaks, CA, USA)
09:30 I-13 Relevance of the
RANKL/RANK/OPG pathway in clinical practise
L. Hofbauer (Marburg, Germany)
ORAL COMMUNICATIONS
OSTEOCLASTS
Chairs: R. Baron (New Haven CT, USA)
A. Zallone (Bari, Italy)
10:00 - 11:00 Main Auditorium
10:00 O-16PKCALPHA IS
DOWNSTREAM OF ALPHAVBETA3 INTEGRIN AND CONTRIBUTES TO ADHESION-INDUCED ERK1/2 ACTIVATION
IN OSTEOCLASTS AND IN CHINESE HAMSTER OVARY (CHO) CELLS
N. Rucci1*, L. Orrù1, C. DiGiacinto1, S. Migliaccio1,
M. Longo1, R. Baron2, A. Teti1
1Department of Experimental Medicine, University of L'Aquila, L'Aquila, Italy
2Department of Cell Biology and Orthopaedics, Yale University School of
Medicine, New Haven, CT., USA
10:12 O-17 TSH
NEGATIVELY REGULATES BOTH OSTEOCLAST AND OSTEOBLAST FORMATION AND SURVIVAL: EFFECTS ON JNK
SIGNALING AND C-JUN TRANSLOCATION
E. Abe1*, R. Marians1, T. Ando1, Y. Li2, H.
Blair2, T. F. Davies1, M. Zaidi1
1The Mount Sinai Bone Program and Bronx VA GRECC, New York, NY, USA
2University of Pittsburgh, Pittsburgh, PA, USA
10:24 O-18 INHIBITION
OF OSTEOCLAST DIFFERENTIATION BY PROTEASE-ACTIVATED RECEPTOR-2
R. Smith1, M. Ransjö2, R. N. Pike1, E. J. Mackie3*
1Department of Biochemistry and Molecular Biology, Monash University, Clayton,
Victoria, Australia
2Department of Oral Cell Biology, Umeå University, Umeå, Sweden
3School of Veterinary Science, University of Melbourne, Parkville, Victoria,
Australia
10:36 O-19 CYTOKINE-ACTIVATED
T-CELLS SUPPORT OSTEOCLASTOGENESIS FROM PERIPHERAL BLOOD MONONUCLEAR CELL PRECURSORS
D. O'Gradaigh*, D. Ireland, J. E. Compston
Bone Research Group, University of Cambridge School of Clinical Medicine, Addenbrooke's
Hospital, Cambridge, UK
10:48 O-20 THE ABSENCE
OF CBL-B CAUSES INCREASED OSTEOCLAST ACTIVITY AND OSTEOPENIA
R. Chiusaroli1*, A. Sanjay1, H. Gu2, R. Baron1
1School of Medicine, Yale University, New Haven, CT, USA
2NIH, Bethesda, MD, USA
11:00 ECTS Annual General
Meeting
Main Auditorium
11:00 - 12:00 Coffee & Posters
12:00 - 14:00 Lunch
WORKSHOP 3
SKELETAL RESPONSE TO MECHANICAL LOAD
Chairs: L. E. Lanyon (London, UK)
S. Migliaccio (Rome, Italy)
12:45 - 14:00 Room A
12:45 I-14 What type of
exercise is beneficial to the skeleton?
A. Heinonen (Tempere, Finland)
13:10 I-15 Neurotransmitter
function in bone
T. Skerry (London, UK)
13:35 I-16 Mechanical
loading, osteocytes and apoptosis
B. Noble (Edinburgh, UK)
WORKSHOP 4
MONITORING RESPONSES TO TREATMENTS
Chairs: S. Ortolani (Milan, Italy)
H. Pols (Rotterdam, The Netherlands)
12:45 - 14:00 Main Auditorium
12:45 I-17 Role of
biochemical markers in monitoring adherence to treatment
R. Eastell (Sheffield, UK)
13:10 I-18 Role of bone
densitometry and quantitative ultrasound techniques in monitoring treatment response
C. C. Glüer (Kiel, Germany)
13:35 I-19 Do we need to
monitor anti-osteoporosis treatment anyway?
J. E. Compston (Cambridge, UK)
SYMPOSIUM 4
GENETICS
Chairs: M. L. Brandi (Florence, Italy)
W. Van Hul (Antwerp, Belgium)
14:00 - 15:00 Main Auditorium
14:00 I-20 Modelling human
genetic bone diseases using transgenic and other approaches
S. Mundlos (Berlin, Germany)
14:30 I-21 Genetic
determinants of osteoporosis
A. Uitterlinden (Rotterdam, The Netherlands)
ORAL COMMUNICATIONS
GENETICS 1
Chairs: M. L. Brandi (Florence, Italy)
W. Van Hul (Antwerp, Belgium)
15:00 - 16:00 Main Auditorium
15:00 O-21 THE LRP5
GENE IS INVOLVED IN DIFFERENT CONDITIONS WITH AN INCREASED BONE DENSITY AS ILLUSTRATED BY
THE IDENTIFICATION OF SIX NOVEL MISSENSE MUTATIONS
L. Van Wesenbeeck1*, E. Cleiren1, J. Gram2, R. K. Beals3,
M. L. Warman4, M. C. deVernejoul5, J. Bollerslev2, W. Van
Hul1
1Dept. Medical Genetics, University of Antwerp, Belgium
2Dept. Endocrinology, Rikshospitalet, Oslo, Norway
3Dept. Orthopaedics and Rehabilitation, Oregon Health Sciences University,
Portland, Oregon, USA
4Dept Genetics, Case Western Reserve Univ, Cleveland, OH, USA
5Laboratoire INSERM U 349, Hôpital Laribosisière, Paris, France
15:12 O-22 ASSOCIATION
OF LRP5 POLYMORPHISMS WITH BONE MINERAL DENSITY IN ELDERLY MEN AND WOMEN
J. B. J. van Meurs1,2*, W. Hugens1, P. P. Arp1, C.
Bartels3, M. Ai3, A. Hofman2, M. Warman3, H.
A. P. Pols1,2, A. G. Uitterlinden1,2
1Department of Internal Medicine, Erasmus MC, Rotterdam, The Netherlands
2Department of Epidemiology and Biostatistics, Erasmus MC, Rotterdam, The
Netherlands
3Department of Genetics, Case Western Reserve University, Cleveland, USA
15:24 O-23 CIRCULATING
AMOUNTS OF OSTEOPROTEGERIN AND RANK LIGAND: GENETIC INFLUENCE AND RELATIONSHIP WITH BONE
MINERAL DENSITY ASSESSED IN FEMALE TWINS
B. Abrahamsen1*, P. Kostenuik2, L. S. Stilgren1, K. Kyvik3,
S. Adamu2, K. Brixen1, B. L. Langdahl4
1Dept of Endocrinology, Odense Univ. Hospital, DK-5000 Odense, Denmark
2Amgen, Metabolic Disorders Research, Thousand Oaks, CA 91320, USA
3The Danish Twin Registry, Institute of Public Health, University of Southern
Denmark, DK-5000 Odense, Denmark
4Univ. Department of Endocrinology C, Aarhus Amtssygehus, DK-8000 Aarhus C,
Denmark
15:36 O-24 BONE
FRACTURES AND AGE AT FRACTURE TIME IS ASSOCIATED WITH ESTROGEN RECEPTOR ALPHA1 GENE
POLYMORPHISMS IN INSTITUTIONALIZED PATIENTS
B. M. Obermayer-Pietsch*, U. Hartl, C. M. Bonelli, A. Fahrleitner-Pammer, J. C.
Piswanger-Sölkner, P. Maritschnegg, G. Leb, H. Dobnig
Dep. of Internal Medicine, Karl-Franzens-University, Graz, Austria
15:48 O-25
INFLUENCE OF SERUM VITAMIN D LEVEL ON EFFECT OF CDX-2 POLYMORPHISM IN THE 1E PROMOTER
OF THE VDR GENE IN DETERMINING BMD
Y. Fang1*, N. F. Barley2, M. Khanji2, J. B. J. van Meurs1,
A. P. Bergink1,3, J. P. T. M. van Leeuwen1, H. A. P. Pols1,3,
J. R. F. Walters2, A. G. Uitterlinden1,3
1Department of Internal Medicine, Erasmus MC, Rotterdam, The Netherlands
2Gastroenterology Section, Faculty of Medicine, Imperial College London, UK
3Department of Epidemiology, Erasmus MC, Rotterdam, The Netherlands
16:00 - 16:20 Coffee
ORAL COMMUNICATIONS
GENETICS 2
Chairs: S. Mundlos (Berlin, Germany)
A. Villa ( Milan, Italy)
16:20 - 17:20 Main Auditorium
16:20 O-26 CHARACTERISATION
OF AN INACTIVATING MUTATION IN OSTEOPROTEGERIN
C. A. Middleton-Hardie*, T. Cundy, I. R. Reid, J. Cornish, D. Naot
University of Auckland, New Zealand
16:32 O-27 INTRON 8
POLYMORPHISM IN CHLORIDE CHANNEL 7 GENE (CLCN7) AND ASSOCIATION WITH BONE MINERAL DENSITY
A. Taranta1*, M. Mirolo2, A. Frattini2, O. M. E. Albagha3,
F. E. A. McGuigan3, D. M. Reid3, P. Vezzoni2, A. Villa2,
A. Teti1, S. H. Ralston3
1Dept of Experimental Medicine, University of L'Aquila, L'Aquila, Italy
2Institute of Biomedical Technology, CNR, Milan, Italy
3Dept of Medicine and Therapeutics, University of Aberdeen, Aberdeen, Scotland,
UK
16:44 O-28 ASSOCIATION
OF GENETIC DISPOSITION FOR ADULT LACTOSE INTOLERANCE TO CALCIUM INTAKE, BONE DENSITY AND
BONE FRACTURES IN POSTMENOPAUSAL WOMEN
B. M. Obermayer-Pietsch1*, C. M. Bonelli1, D. E. Walter1,
A. Fahrleitner-Pammer1, A. Berghold2, W. Goessler3, V.
Stepan1, H. Dobnig1, G. Leb1, W. Renner4
1Dep. of Internal Medicine, Karl-Franzens-University, Graz, Austria
2Insitute for Medical Informatics, Statistics and Documentation,
Karl-Franzens-University, Graz, Austria
3Institute of Chemistry - Analytical Chemistry, Karl-Franzens-University, Graz,
Austria
4Institute of Molecularbiological Analytics, Graz, Austria
16:56 O-29 LOSS OF
FRA-2 EXPRESSION LEADS TO OSTEOPOROSIS
A. Hoebertz1*, R. Eferl1, F. Karreth1, A. F. Schilling2,
M. Priemel2, M. Amling2, E. F. Wagner1
1Research Institute of Molecular Pathology (IMP), Vienna, Austria
2Department of Trauma and Reconstructive Surgery, University School of
Medicine, Hamburg, Germany
17:08 O-30 TRANSGENIC
OVEREXPRESSION OF IGFBP-2 PRODUCES SEX- AND SITE-SPECIFIC INHIBITORY EFFECTS ON GH-INDUCED
SKELETAL CHANGES IN MICE
F. Eckstein1*, D. Bürklein1, T. Fisch2, M. Priemel3,
R. Wanke2, A. Hoeflich4, M. Amling3, S. Mohan5,
E. Wolf4
1Intitute of Anatomy, LMU München, Germany
2Institute of Veterinary Pathology, LMU München, Germany
3Department for Trauma and Reconstructive Surgery, Experimental Surgery,
Hamburg University, Germany
4Institute of Molecular Animal Breeding, LMU München, Germany
5Jerry L Petttis VA Medical Center, Loma Linda, CA, USA
17:20 - 17:40 Coffee
SATELLITE SYMPOSIUM
PREVENT, TREAT AND MAINTAIN: A
NEW PARADIGM IN OSTEOPOROSIS MANAGEMENT
Supported by Eli Lilly & Co
Chair: G. Russell
17:40 - 19:40 Main Auditorium
A brief Question & Answer session will follow each presentation.
17:40 - 17:50 Opening Remarks
Graham Russell
17:50 - 18:25 Antiresorptives Long Term Effects on Bone
Jan Stepan
18:25 - 19:00 Bone Formation Agents: An Innovative Treatment for
Severe Osteoporosis
Robert Marcus
19:00 - 19:35 How to Optimize Osteoporosis Management: Short-term vs.
Long-term treatment
Bruce Ettinger
19:35 - 19:40 Closing Remarks |
